Arena Pharmaceuticals News

The FDA has two multi-billion dollar decisions to make this summer regarding obesity and weight loss treatments.

The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics around the investing world.

Shares of Bayer slip, but Onyx Pharmaceuticals moves up following word that a Phase 3 trial of Nexavar tablets in patients with certain lung cancers failed to meet its primary endpoint of improving overall survival.

Traders who are comfortable with a high level of risk/reward frequently will gravitate to the small-cap space where big gains in a short amount of time are commonplace.

Arena Pharmaceuticals, Inc. today announced the completion of an underwritten public offering of 12,650,000 shares of its common stock, including 1,650,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters.

Researchers say the U.S. approved more new medicines in less time than Europe and Canada in the last decade, challenging long-standing criticisms that the Food and Drug Administration lags behind its peers in clearing important new drugs.

SINA released its first-quarter results yesterday, and investors have responded favorably despite the Chinese Internet company's first-quarter loss, which was $13.3 million or $0.21 per share.

U.S. stock-index futures fluctuated between gains and losses as speculation reports today may show increases in housing starts and industrial production offset concern Greece will be forced to exit the euro.

Shares of the following companies may have unusual moves in U.S. trading tomorrow.

Arena Pharmaceuticals, Inc. shares climbed high, as the market pretty much believing that FDA approval of the company's experimental obesity drug Lorcaserin is guaranteed.

Eisai Co., Ltd. announced recently that its U.S. subsidiary Eisai Inc. has expanded the marketing and supply agreement it concluded with Arena Pharmaceuticals GmbH, the Swiss subsidiary of U.S.-based Arena Pharmaceuticals Inc.

As Pfizer 's rheumatoid arthritis pill and Arena Pharmaceuticals' weight-loss drug got positive nods from federal advisory panels, the role of biotech companies in finding new treatments for major medical disorders is getting renewed investor attention.

Here's a "wow" stock for you: Arena Pharmaceuticals' 72% surge on an FDA panel's obesity-drug backing brings the shares' year-to-date gain to 234%. This is a small-cap stock beloved by a handful of hedge funds; it's not one you see in big mutual-fund or ETF doses.

PHARMACEUTICALS FDA panel endorses weight-loss drug Arena Pharmaceuticals jumped the most ever Friday after the company's weight-loss pill gained the backing of an advisory panel, putting two obesity drugs in line for U.S. approval almost two years after regulators rejected them as too risky.

Among the stocks that could see active trade in Friday's session are Arena Pharmaceuticals Inc., Nordstrom Inc.

Arena Pharmaceuticals Inc. jumped the most ever after the company's weight-loss pill gained the backing of an advisory panel, putting two obesity drugs in line for U.S. approval almost two years after regulators rejected them as too risky.

Lorcaserin, an investigational obesity drug, was given a positive recommendation by the Endocrinologic and Metabolic Drugs Advisory Committee, which advises the Food and Drug Administration .

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Arena Pharmaceuticals, Inc.

The firm currently has a $1.00 price target on the stock, down from their previous price target of $9.00. Several other analysts have also recently commented on the stock.

Their main focus is on U.S. equities with the potential to deliver gains of 50%-100% or more.